Views

CrossRef citations to date

Altmetric

Original Articles

Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study

Jordan E. LakeUniversity of California, Los Angeles, CA, USACorrespondence[email protected]

Sophie SeangUniversity of California, Los Angeles, CA, USA

Theodoros KelesidisUniversity of California, Los Angeles, CA, USA

Diana H. LiaoUniversity of California, Los Angeles, CA, USA

Howard N. HodisUniversity of SouthernCalifornia, Los Angeles, CA, USA

James H. SteinUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Judith S. CurrierUniversity of California, Los Angeles, CA, USA

show all

Figures & data

Table 1. Baseline demographic and clinical characteristics.Footnote^*

Download CSV Display Table

Figure 1. Median 6-week changes in blood pressure with telmisartan therapy. SBP: systolic blood pressure; DBP: diastolic blood pressure; W: week.

Table 2. Median baseline and 6-week changes in brachial artery flow-mediated dilation on telmisartan therapy.Footnote^*

Download CSV Display Table

Figure 2. Median 6-week changes in brachial artery flow-mediated dilation with telmisartan therapy. ABC: abacavir; TDF: tenofovir; PI: protease inhibitor.

Table 3. Median baseline and 6-week changes in metabolic and immunoinflammatory markers with telmisartan therapy.Footnote^*

Download CSV Display Table

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study

Table 1. Baseline demographic and clinical characteristics.Footnote^*

Table 2. Median baseline and 6-week changes in brachial artery flow-mediated dilation on telmisartan therapy.Footnote^*

Table 3. Median baseline and 6-week changes in metabolic and immunoinflammatory markers with telmisartan therapy.Footnote^*

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study

Figures & data

Table 1. Baseline demographic and clinical characteristics.Footnote*

Table 2. Median baseline and 6-week changes in brachial artery flow-mediated dilation on telmisartan therapy.Footnote*

Table 3. Median baseline and 6-week changes in metabolic and immunoinflammatory markers with telmisartan therapy.Footnote*

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1. Baseline demographic and clinical characteristics.Footnote^*

Table 2. Median baseline and 6-week changes in brachial artery flow-mediated dilation on telmisartan therapy.Footnote^*

Table 3. Median baseline and 6-week changes in metabolic and immunoinflammatory markers with telmisartan therapy.Footnote^*